News/ News/ R&D Sanofi’s venglustat bombs again, but isn’t dead yet Phil Taylor kidney disease, nephrology, rare disease, Sanofi, Sanofi Genzyme, venglustat 0 Comment Shortly after failing a Parkinson’s disease study, Sanofi’s venglustat has missed the mark in another trial in autosomal Share X Sanofi’s venglustat bombs again, but isn’t dead yet https://pharmaphorum.com/news/sanofis-venglustat-bombs-again-but-isnt-dead-yet/